Claims for Patent: 6,896,885

Summary for Patent: 6,896,885

Title:	Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma
Abstract:	The present invention discloses combined therapies for treating hematologic malignancies, including B cell lymphomas and leukemias or solid non-hematologic tumors, comprising administration of anti-cytokine antibodies or antagonists to inhibit the activity of cytokines which play a role in perpetuating the activation of B cells. The administration of such antibodies and antagonists, particularly anti-IL10 antibodies and antagonists, is particularly useful for avoiding or decreasing the resistance of hematologic malignant cells or solid tumor cells to chemotherapeutic agents and anti-CD20 or anti-CD22 antibodies. The invention also provides combination therapies for solid tumors having B cell involvement comprising the administration of an anti-cytokine antibody and a B cell depleting antibody such as RITUXAN.RTM. (rituximab).
Inventor(s):	Hanna; Nabil (Rancho Santa Fe, CA)
Assignee:	Biogen Idec Inc. (San Diego, CA)
Application Number:	09/822,672
Patent Claims:	1. A method of treating B cell lymphoma in a patient in need of such treatment which method includes the administration of anti-IL10 antibody and at least one B cell depleting antibody. 2. The method of claim 1 wherein said B cell depleting antibody binds to a B cell antigen from the group consisting of CD19, CD20, CD22, CD23, CD27, CD37, CD53, CD72, CD73, CD74, CD.omega.78, CD79a, CD79b, CD80, CD81, CD82, CD83, CDw84, CD85 and CD86. 3. A method of treating B cell lymphoma in a patient in need of such treatment which method comprises the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 or anti-CD22 antibody. 4. A method of treating B cell lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 antibody. 5. A method of treating non-Hodgkin's lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting antibody. 6. A method of treating non-Hodgkin's lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting anti-CD20 antibody. 7. A method of treating non-Hodgkin's lymphoma in a patient in need of such treatment comprising the administration of an anti-IL10 antibody and a B cell depleting anti-CD22 antibody. 8. The method of claim 4 wherein said antibody is rituximab (ATCC No. HB-69119). 9. The method of claim 6 wherein said antibody is rituximab (ATCC No. HB-69119). 10. A combination therapy for treating B cell lymphoma in a patient comprising the administration of a therapeutically effective amount of an anti-IL10 antibody, a B cell depleting anti-CD20 antibody and chemotherapy. 11. The method of claim 10 wherein said anti CD20 antibody is rituximab (ATTC No. HB-69119). 12. The method of claim 10 wherein said patient has relapsed following previous treatment with a B cell depleting antibody. 13. The method of claim 12 wherein said antibody is rituximab (ATTC No. HB-69119). 14. The method of claim 2 wherein the B cell depleting antibody binds CD20. 15. The method of claim 2 wherein the B cell depleting antibody binds CD23. 16. The method of claim 14 wherein said antibody is a chimeric anti-CD20 antibody. 17. The method of claim 16 wherein said chimeric anti-CD20 antibody is rituximab (ATCC No. HB-69119). 18. The method of claim 1 wherein said treating is combined with chemotherapy. 19. The method of claim 1 wherein said B cell lymphoma is selected from the group consisting of low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intennediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL and Waldenstrom's Macroglobulinemia. 20. The method of claim 1 wherein said antibodies are administered by intravenous, intramuscular, intratumeoral or intraperitoneal administration. 21. The method of claim 18 wherein said chemotherapy is selected from the group consisting of CHOP, ICE, Mitozantrone, Cytarabine, DVP, ATRA, Idarubicin, hoelzer chemotherapy regime, La La chemotherapy regime, ABVD, CEOP, 2-CdA, FLAG & IDA (with or without subsequent G-CSF treatment), VAD, M&P, C-Weekly, ABCM, MOPP, DHAP, daunorubicin, doxorubicin, methotrexate, and cisplatin. 22. The method of claim 1 wherein either or both of said antibodies are human, humanized or chimeric antibodies. 23. The method of claim 1 wherein the dosage of said antibodies range from 0.01 to 1000 mg/kg body weight. 24. A method of treating B cell lymphoma in a patient in need of such treatment comprising the administration of an anti-R10 antibody and a B cell depleting anti-CD20 antibody, wherein the anti-CD20 antibody comprises the heavy chain variable region of C2B8, and the light chain variable region of C2B8. 25. The method of claim 24, wherein the anti-CD20 antibody further comprises human constant regions. 26. The method of claim 6, wherein the anti-CD20 antibody comprises the heavy chain variable region of C2B8, and the light chain variable region of C2B8. 27. The method of claim 26, wherein the anti-CD20 antibody further comprises human constant regions. 28. The method of claim 10, wherein the anti-CD20 antibody comprises the heavy chain variable region of C2B8, and the light chain variable region of C2B8. 29. The method of claim 28, wherein the anti-CD20 antibody further comprises human constant regions.

Details for Patent 6,896,885

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2020-03-31
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2020-03-31
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2020-03-31